More White than Black and Hispanic patients receive buprenorphine, naloxone, benzodiazepines in 180 days after index event
Persons receiving medication for opioid use disorder more likely to be older, White and to have public insurance
Increase seen in age-adjusted drug overdose death rates involving methamphetamine, cocaine; decrease reported in death rates involving oxycodone
Median monthly retention rate was 22.2 percent during January 2016 through April 2022
The U.S. Food and Drug Administration approved OTC Narcan nasal spray last month to be sold without a prescription
Conditioned open-label placebo had no impact on the 90-day methadone dose, but did improve sleep quality
Increases also seen for coprescribing with opioids
However, fewer than one in 20 individuals receive buprenorphine
Significant associations seen for suicide deaths with opioid prescriptions per capita, having any, high-dose, long-term opioid prescription
Rates of precipitated withdrawal are less than 1 percent